免疫組織化学(IHC)の世界市場予測(~2028):製品別、用途別、エンドユーザー別

【英語タイトル】Immunohistochemistry (IHC) Market by Product (Antibodies, Reagents, Equipment, Kits), Application (Diagnostics (Cancer, Infectious, Autoimmune Diseases), Research, Forensic), End Users (Diagnostic laboratories, Research Institute) - Global Forecast to 2028

MarketsandMarketsが出版した調査資料(BT4780-23)・商品コード:BT4780-23
・発行会社(調査会社):MarketsandMarkets
・発行日:2023年6月9日
・ページ数:399
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥722,700見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥970,900見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥1,189,900見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

マーケッツアンドマーケッツでは、世界の免疫組織化学(IHC)市場規模が2023年から2028年の予測期間中に7.4%の年平均成長率で、2023年の32億ドルから2028年までに47億ドルに達すると予測しています。当調査資料では、免疫組織化学(IHC)の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別(抗体、試薬、機器、キット)分析、用途別(診断用、研究用、法医学用)分析、エンドユーザー別(病院&診断研究所、学術&研究機関、その他)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ)分析、競争状況などの項目を掲載しています。なお、当書に掲載されている企業情報には、F. Hoffman-La Roche AG (Switzerland)、Danaher Corporation (US)、Agilent Technologies, Inc. (US)などが含まれています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界の免疫組織化学(IHC)市場規模:製品別
  - IHC抗体の市場規模
  - IHC試薬の市場規模
  - IHC機器の市場規模
  - IHCキットの市場規模
・世界の免疫組織化学(IHC)市場規模:用途別
  - 診断用免疫組織化学(IHC)の市場規模
  - 研究用免疫組織化学(IHC)の市場規模
  - 法医学用免疫組織化学(IHC)の市場規模
・世界の免疫組織化学(IHC)市場規模:エンドユーザー別
  - 病院&診断研究所における市場規模
  - 学術&研究機関における市場規模
  - その他エンドユーザーにおける市場規模
・世界の免疫組織化学(IHC)市場規模:地域別
  - 北米の免疫組織化学(IHC)市場規模
  - ヨーロッパの免疫組織化学(IHC)市場規模
  - アジア太平洋の免疫組織化学(IHC)市場規模
  - 中南米の免疫組織化学(IHC)市場規模
  - 中東/アフリカの免疫組織化学(IHC)市場規模
・競争状況
・企業情報

“世界の免疫組織化学(IHC)市場は、2023年の32億米ドルから2028年には47億米ドルに達し、2023年から2028年の予測期間中の年平均成長率は7.4%と予測”
市場成長の主な原動力は、癌の有病率の増加と、癌の診断および管理におけるIHC検査の膨大な応用です。また、コンパニオン診断薬の開発やコンパニオン診断薬とIHC検査の統合は、個別化医療を促進し、医薬品開発と承認プロセスを支援し、市場の可能性を拡大し、患者の転帰を改善し、研究協力を奨励し、免疫組織化学(IHC)市場に成長機会を提供しています。

“試薬セグメント別では組織染色が最大シェアを占める見込み”
2022年、免疫組織化学(IHC)組織染色市場が最大のシェアを占めました。免疫組織化学(IHC)では、標的の相対的局在は、多重染色技術の助けを借りて1枚のスライドですべての相対的標的を可視化することによって得ることができます。多重染色とは、1枚のスライド上で2つ以上のターゲットを検出することで、逐次染色、同時染色、色素を用いた多段階染色などの方法があります。したがって、1つの組織切片で抗原部位を多重染色できる高度な能力は、実験的かつ使いやすい利点をもたらし、これが組織染色市場を牽引すると期待されています。

“用途別では研究用途分野が第2位のシェア”
2022年、研究用途が第2位のシェアを占めました。研究用途におけるIHCには、抗腫瘍薬開発やバイオマーカー探索が含まれます。IHCは、正常細胞や異常細胞における発現の変化を調べるために、特定のタンパク質の発現や膜、細胞質、核内でのタンパク質の共局在を調べるのに役立ちます。研究アプリケーションで使用される高スループットの自動IHCプラットフォームは、スライド間の染色の均一性を維持するのに役立ちます。このような利点から、IHC技術は発生(発生学)研究、幹細胞研究、薬物検査にも広く使用されています。

“アジア太平洋地域は免疫組織化学(IHC)市場で最も急成長している地域”
免疫組織化学(IHC)市場は、北米、ヨーロッパ、アジア太平洋、ラテンアメリカ(LATAM)、中東・アフリカ(MEA)に区分されます。アジア太平洋地域は高成長市場であり、研究および臨床応用において最新の技術的に高度な製品(アッセイや診断キットのような)が急速に採用されているのが特徴です。この要因は、同地域における老人人口の増加と相まって、急成長の主な要因となっています。

本レポートのために実施した一次インタビューは以下のように分類できます:
– 回答者別 供給側70%、需要側30%
– 役職別 管理職:55%、CXO:20%、経営幹部:25%
– 地域別 北米:50%、欧州:20%、アジア太平洋地域:20%、アジア太平洋地域:10%

免疫組織化学(IHC)市場の主要プレイヤーは、F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US)です。

調査範囲
本レポートは免疫組織化学(IHC)市場の詳細情報を提供します。製品、用途、エンドユーザー、地域などの異なるセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。また、主要な市場プレイヤーの企業プロフィールや最近の動向、主要な市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主な利点
本レポートは、免疫組織化学(IHC)市場全体とそのサブセグメントについて、最も近似した収益数字を提供することで、市場リーダー/新規参入者に役立ちます。また、利害関係者が競争状況をより良く理解し、より多くの洞察を得ることで、自社のビジネスをより良く位置づけ、適切な市場参入戦略を立てるのに役立ちます。本レポートは、関係者が市場動向を理解し、主要な市場促進要因、阻害要因、動向、課題、機会に関する情報を提供することを可能にします。

本レポートは、以下のポイントに関する洞察を提供します:
– 主な促進要因(高齢者人口の増加と癌疾患の有病率の増加が市場成長にプラスの影響を与える、IHCにおける技術的進歩、IHC検査に対する償還の利用可能性、デジタルパソロジーの採用が市場成長を促進)、阻害要因(代替技術の利用可能性、高度の統合)、機会(個別化医療に対する需要の増加、コンパニオン診断の重要性の高まり、新興国における成長機会、IHCにおける人工知能の応用)、課題(製品の不具合とリコール、厳しい規制要件、標準化の欠如)分析
– 製品開発/イノベーション: 新しく発売された製品に関する詳細な洞察、免疫組織化学(IHC)市場の技術評価
– 市場開発: 有利な市場に関する包括的な情報 – 当レポートは様々な地域の免疫組織化学(IHC)市場を分析
– 市場の多様化: 免疫組織化学(IHC)市場における新製品、未開拓の地域、最近の開発、投資に関する詳細な情報
– 競争力の評価: 免疫組織化学(IHC)市場におけるF. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US)など、主要企業の市場シェア、成長戦略、主要企業のサービス提供などの詳細な評価
また、本レポートは、関係者がIHC市場動向を理解するのに役立ち、主要な市場促進要因、阻害要因、課題、および機会に関する情報を提供

❖ レポートの目次 ❖

1 INTRODUCTION 47
1.1 STUDY OBJECTIVES 47
1.2 MARKET DEFINITION 47
1.2.1 INCLUSIONS & EXCLUSIONS 48
TABLE 1 IMMUNOHISTOCHEMISTRY MARKET: INCLUSIONS & EXCLUSIONS 48
1.3 MARKET SCOPE 49
1.3.1 MARKETS COVERED 49
FIGURE 1 IMMUNOHISTOCHEMISTRY MARKET SEGMENTATION 49
1.3.2 YEARS CONSIDERED 50
1.4 CURRENCY 50
1.5 LIMITATIONS 50
1.6 STAKEHOLDERS 51
1.7 SUMMARY OF CHANGES 51
1.7.1 RECESSION IMPACT 52
2 RESEARCH METHODOLOGY 53
2.1 RESEARCH DATA 53
FIGURE 2 IHC MARKET: RESEARCH DESIGN METHODOLOGY 53
2.1.1 SECONDARY DATA 54
2.1.2 PRIMARY DATA 54
FIGURE 3 IHC MARKET: BREAKDOWN OF PRIMARIES 55
2.2 MARKET ESTIMATION METHODOLOGY 56
FIGURE 4 IHC MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022 56
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2022 57
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 58
FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 58
2.3 MARKET GROWTH RATE PROJECTIONS 59
FIGURE 7 IHC MARKET (SUPPLY SIDE): CAGR PROJECTIONS 60
FIGURE 8 IHC MARKET (DEMAND SIDE): GROWTH ANALYSIS OF DEMAND-SIDE DRIVERS 61
2.3.1 DATA TRIANGULATION 62
FIGURE 9 DATA TRIANGULATION METHODOLOGY 62
2.4 RESEARCH ASSUMPTIONS 63
2.5 RISK ANALYSIS 63
2.6 RECESSION IMPACT 63
TABLE 2 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 64
TABLE 3 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 64
TABLE 4 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 64
3 EXECUTIVE SUMMARY 65
FIGURE 10 IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 65
FIGURE 11 IMMUNOHISTOCHEMISTRY MARKET SHARE, BY APPLICATION, 2022 66
FIGURE 12 IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2023 VS. 2028 66
FIGURE 13 IMMUNOHISTOCHEMISTRY MARKET: REGIONAL SNAPSHOT 67
4 PREMIUM INSIGHTS 68
4.1 IMMUNOHISTOCHEMISTRY MARKET OVERVIEW 68
FIGURE 14 TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET GROWTH 68
4.2 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET SHARE, BY END USER AND COUNTRY (2022) 69
FIGURE 15 HOSPITALS & DIAGNOSTIC LABORATORIES SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC IHC MARKET IN 2022 69
4.3 IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE 70
FIGURE 16 PRIMARY ANTIBODIES SEGMENT TO LEAD IHC ANTIBODIES MARKET DURING FORECAST PERIOD 70
5 MARKET OVERVIEW 71
5.1 INTRODUCTION 71
5.2 MARKET DYNAMICS 71
FIGURE 17 IHC MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES 71
TABLE 5 IHC MARKET: IMPACT ANALYSIS 72
5.2.1 DRIVERS 73
5.2.1.1 Rising geriatric population and growing prevalence of cancer 73
TABLE 6 ESTIMATED PERCENTAGE INCREASE IN GERIATRIC POPULATION, BY REGION (2022–2050) 73
FIGURE 18 CANCER INCIDENCE, BY REGION AND TYPE OF CANCER, 2020 74
5.2.1.2 Technological advancements in IHC 74
5.2.1.3 Availability of reimbursements for IHC tests 75
TABLE 7 CPT CODES FOR IHC PROCEDURES 75
5.2.1.4 Adoption of digital pathology 76
5.2.2 RESTRAINTS 77
5.2.2.1 Availability of alternative technologies 77
5.2.2.2 High degree of consolidation 78
TABLE 8 MAJOR ACQUISITIONS IN MARKET, 2020–2023 78
5.2.3 OPPORTUNITIES 78
5.2.3.1 Increasing demand for personalized medicine 78
FIGURE 19 GROWTH OF PERSONALIZED MEDICINES APPROVED BY FDA, 2015–2022 79
5.2.3.2 Growing significance of companion diagnostics 79
5.2.3.3 Growth opportunities in emerging countries 80
5.2.3.4 Application of artificial intelligence in IHC 80
5.2.4 CHALLENGES 81
5.2.4.1 Product failures and recalls 81
5.2.4.2 Stringent regulatory requirements 81
5.2.4.3 Lack of standardization 81
5.3 ELEMENTS OF UNCERTAINTY IN IHC MARKET 82
FIGURE 20 IHC MARKET: SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH 82
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 83
FIGURE 21 REVENUE SHIFT & NEW REVENUE POCKETS FOR IHC PROVIDERS 83
5.5 PRICING ANALYSIS 83
TABLE 9 AVERAGE SELLING PRICE OF SOME IHC EQUIPMENT, REAGENTS, AND KITS (2022) 83
5.5.1 AVERAGE SELLING PRICE TRENDS 84
5.6 VALUE CHAIN ANALYSIS 84
FIGURE 22 VALUE CHAIN ANALYSIS OF IHC MARKET: RAW MATERIAL AND MANUFACTURING PHASE TO CONTRIBUTE MAXIMUM VALUE 84
5.6.1 RESEARCH AND PRODUCT DEVELOPMENT 85
5.7 ECOSYSTEM ANALYSIS 86
FIGURE 23 IHC MARKET: ECOSYSTEM ANALYSIS 86
TABLE 10 SUPPLY CHAIN ECOSYSTEM 86
5.8 TECHNOLOGY ANALYSIS 87
5.9 PATENT ANALYSIS 89
FIGURE 24 IHC MARKET: PATENT ANALYSIS, 2014–2023 89
TABLE 11 INDICATIVE LIST OF PATENTS IN IHC MARKET 90
5.10 REGULATORY ANALYSIS 91
5.10.1 US 91
TABLE 12 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES 91
FIGURE 25 US: REGULATORY PROCESS FOR IVD DEVICES 92
5.10.2 CANADA 93
FIGURE 26 CANADA: REGULATORY PROCESS FOR IVD DEVICES 93
5.10.3 EUROPE 93
TABLE 13 EUROPE: CLASSIFICATION OF IVD DEVICES 93
FIGURE 27 EUROPE: REGULATORY PROCESS FOR IVD DEVICES 94
5.10.4 JAPAN 95
FIGURE 28 JAPAN: REGULATORY PROCESS FOR IVD DEVICES 95
TABLE 14 JAPAN: CLASSIFICATION OF IVD REAGENTS 95
TABLE 15 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 96
5.10.5 CHINA 96
TABLE 16 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 96
5.10.6 INDIA 96
FIGURE 29 INDIA: REGULATORY PROCESS FOR IVD DEVICES 97
5.10.7 BRAZIL 97
FIGURE 30 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES 98
5.11 PORTER’S FIVE FORCES ANALYSIS 98
TABLE 17 IMPACT OF PORTER’S FIVE FORCES ANALYSIS ON IHC MARKET 98
5.11.1 THREAT OF NEW ENTRANTS 99
5.11.2 THREAT OF SUBSTITUTES 99
5.11.3 BARGAINING POWER OF BUYERS 99
5.11.4 BARGAINING POWER OF SUPPLIERS 99
5.11.5 INTENSITY OF COMPETITIVE RIVALRY 100
5.12 KEY CONFERENCES AND EVENTS IN 2023–2024 100
TABLE 18 IMMUNOHISTOCHEMISTRY MARKET: LIST OF CONFERENCES AND EVENTS 100
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 101
FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IMMUNOHISTOCHEMISTRY PRODUCTS 101
FIGURE 32 BUYING CRITERIA FOR IMMUNOHISTOCHEMISTRY PRODUCTS 101
6 IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT 102
6.1 INTRODUCTION 103
TABLE 19 IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 103
6.2 ANTIBODIES 103
TABLE 20 IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY REGION, 2021–2028 (USD MILLION) 104
TABLE 21 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 22 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 23 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 24 IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 106
6.2.1 PRIMARY ANTIBODIES 106
6.2.1.1 Wide applications in diagnostics and research to support demand for primary antibodies 106
TABLE 25 IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY REGION, 2021–2028 (USD MILLION) 107
TABLE 26 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 27 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 28 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 108
6.2.2 SECONDARY ANTIBODIES 108
6.2.2.1 Signal amplification through conjugation and comparatively easy manufacturing to fuel market 108
TABLE 29 IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES, BY REGION, 2021–2028 (USD MILLION) 109
TABLE 30 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 31 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 32 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 110
6.3 REAGENTS 111
TABLE 33 IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY REGION, 2021–2028 (USD MILLION) 111
TABLE 34 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 35 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 36 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 37 IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 113
6.3.1 HISTOLOGICAL STAINS 113
6.3.1.1 Developments in concurrent detection of multiple antigenic sites and cancer disease progression studies to propel market 113
TABLE 38 IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS, BY REGION, 2021–2028 (USD MILLION) 114
TABLE 39 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 40 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 41 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS, BY COUNTRY, 2021–2028 (USD MILLION) 115
6.3.2 BLOCKING SERA AND REAGENTS 116
6.3.2.1 Blocking sera and reagents to prevent nonspecific binding and reduce background noise & potentially false-positive results 116
TABLE 42 IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS, BY REGION, 2021–2028 (USD MILLION) 116
TABLE 43 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 44 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 45 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 117
6.3.3 CHROMOGENIC SUBSTRATES 118
6.3.3.1 Chromogenic substrates segment to register highest growth during forecast period 118
TABLE 46 IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES, BY REGION, 2021–2028 (USD MILLION) 118
TABLE 47 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 48 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 49 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2021–2028 (USD MILLION) 119
6.3.4 FIXATION REAGENTS 120
6.3.4.1 North America projected to be largest market for fixation reagents 120
TABLE 50 IMMUNOHISTOCHEMISTRY MARKET FOR FIXATION REAGENTS, BY REGION, 2021–2028 (USD MILLION) 120
TABLE 51 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR FIXATION REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 52 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR FIXATION REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 53 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR FIXATION REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 121
6.3.5 DILUENTS 122
6.3.5.1 Need of diluents for preparation of antibody solutions to promote market growth 122
TABLE 54 IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS, BY REGION, 2021–2028 (USD MILLION) 122
TABLE 55 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 56 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS, BY COUNTRY, 2021–2028 (USD MILLION) 123
TABLE 57 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS, BY COUNTRY, 2021–2028 (USD MILLION) 123
6.3.6 ORGANIC SOLVENTS 124
6.3.6.1 Organic solvents to prevent physical damage in specimens and improve clarity while visualizing tissue samples 124
TABLE 58 IMMUNOHISTOCHEMISTRY MARKET FOR ORGANIC SOLVENTS, BY REGION, 2021–2028 (USD MILLION) 124
TABLE 59 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ORGANIC SOLVENTS, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 60 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ORGANIC SOLVENTS, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 61 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ORGANIC SOLVENTS, BY COUNTRY, 2021–2028 (USD MILLION) 125
6.3.7 PROTEOLYTIC ENZYMES 125
6.3.7.1 Proteolytic enzymes improve accessibility of target antibodies 125
TABLE 62 IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES, BY REGION, 2021–2028 (USD MILLION) 126
TABLE 63 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 64 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 65 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 127
6.3.8 OTHER REAGENTS 128
TABLE 66 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER REAGENTS, BY REGION, 2021–2028 (USD MILLION) 128
TABLE 67 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 68 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 69 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 130
6.4 EQUIPMENT 130
TABLE 70 IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY REGION, 2021–2028 (USD MILLION) 130
TABLE 71 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 72 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 73 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 74 IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 132
6.4.1 SLIDE-STAINING SYSTEMS 132
6.4.1.1 Development of high-throughput staining systems to drive market growth 132
TABLE 75 IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY REGION, 2021–2028 (USD MILLION) 133
TABLE 76 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 77 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 78 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 134
6.4.2 TISSUE PROCESSING SYSTEMS 135
6.4.2.1 Technological advancements and need for automation due to lack of skilled workforce to fuel market 135
TABLE 79 IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY REGION, 2021–2028 (USD MILLION) 135
TABLE 80 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 81 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 82 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 137
6.4.3 SLIDE SCANNERS 137
6.4.3.1 Development of advanced multiplexed IHC scanners to drive market growth 137
TABLE 83 IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY REGION, 2021–2028 (USD MILLION) 138
TABLE 84 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 85 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY COUNTRY, 2021–2028 USD MILLION) 139
TABLE 86 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY COUNTRY, 2021–2028 (USD MILLION) 139
6.4.4 OTHER EQUIPMENT 140
TABLE 87 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY REGION, 2021–2028 (USD MILLION) 140
TABLE 88 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 140
TABLE 89 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 90 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 141
6.5 KITS 142
TABLE 91 IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY REGION, 2021–2028 (USD MILLION) 142
TABLE 92 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 93 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY COUNTRY, 2021–2028 (USD MILLION) 143
TABLE 94 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY COUNTRY, 2021–2028 (USD MILLION) 143
TABLE 95 IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 144
6.5.1 HUMAN IMMUNOHISTOCHEMISTRY KITS 144
6.5.1.1 Increasing focus on cancer research to fuel market growth 144
TABLE 96 IMMUNOHISTOCHEMISTRY MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY REGION, 2021–2028 (USD MILLION) 144
TABLE 97 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 98 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 99 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2021–2028 (USD MILLION) 146
6.5.2 ANIMAL IMMUNOHISTOCHEMISTRY KITS 146
6.5.2.1 Increasing preclinical drug testing to boost market 146
TABLE 100 IMMUNOHISTOCHEMISTRY MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY REGION, 2021–2028 (USD MILLION) 146
TABLE 101 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 102 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 103 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2021–2028 (USD MILLION) 148
7 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION 149
7.1 INTRODUCTION 150
TABLE 104 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 150
7.2 DIAGNOSTIC APPLICATIONS 150
TABLE 105 IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 151
TABLE 106 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 107 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 152
TABLE 108 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 152
TABLE 109 IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 153
7.2.1 CANCER 153
7.2.1.1 Rise in incidence rate of cancer and growing use of IHC tests for cancer diagnostics to drive market 153
TABLE 110 COMMON CANCER MARKERS FOR IMMUNOHISTOCHEMICAL DIAGNOSIS 154
TABLE 111 IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY REGION, 2021–2028 (USD MILLION) 155
TABLE 112 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 155
TABLE 113 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 114 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 156
7.2.2 INFECTIOUS DISEASES 157
7.2.2.1 Growing prevalence of infectious diseases and rising awareness of early diagnosis to propel market 157
TABLE 115 COMMON INFECTIOUS DISEASE MARKERS/ANTIGENS FOR IMMUNOHISTOCHEMICAL DIAGNOSIS 157
TABLE 116 IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 158
TABLE 117 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 158
TABLE 118 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 159
TABLE 119 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 159
7.2.3 NEPHROLOGICAL DISEASES 160
7.2.3.1 Wide application of IHC in transplant rejection expected to support market growth 160
TABLE 120 IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY REGION, 2021–2028 (USD MILLION) 160
TABLE 121 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 122 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 123 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 162
7.2.4 AUTOIMMUNE DISEASES 162
7.2.4.1 Availability of numerous primary antibodies and rapid processing of results to drive market 162
TABLE 124 IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2021–2028 (USD MILLION) 163
TABLE 125 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 163
TABLE 126 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 127 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 164
7.2.5 NEUROLOGICAL DISEASES 165
7.2.5.1 Increasing global burden of neurological diseases to propel market growth 165
TABLE 128 COMMON IMMUNOHISTOCHEMISTRY MARKERS FOR CENTRAL NERVOUS SYSTEM 165
TABLE 129 IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2021–2028 (USD MILLION) 166
TABLE 130 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 166
TABLE 131 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 167
TABLE 132 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 167
7.2.6 OTHER DISEASES 167
TABLE 133 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY REGION, 2021–2028 (USD MILLION) 168
TABLE 134 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 168
TABLE 135 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 169
TABLE 136 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 169
7.3 RESEARCH APPLICATIONS 170
TABLE 137 IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 170
TABLE 138 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 170
TABLE 139 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 171
TABLE 140 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 171
TABLE 141 IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 172
7.3.1 DRUG DEVELOPMENT & TESTING 172
7.3.1.1 Quantitative image analysis makes IHC techniques ideal for drug testing 172
TABLE 142 IMMUNOHISTOCHEMISTRY MARKET FOR DRUG DEVELOPMENT & TESTING, BY REGION, 2021–2028 (USD MILLION) 173
TABLE 143 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DRUG DEVELOPMENT & TESTING, BY COUNTRY, 2021–2028 (USD MILLION) 173
TABLE 144 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DRUG DEVELOPMENT & TESTING, BY COUNTRY, 2021–2028 (USD MILLION) 174
TABLE 145 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR DRUG DEVELOPMENT & TESTING, BY COUNTRY, 2021–2028 (USD MILLION) 174
7.3.2 OTHER RESEARCH APPLICATIONS 175
TABLE 146 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 175
TABLE 147 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 175
TABLE 148 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 176
TABLE 149 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 176
7.4 FORENSIC APPLICATIONS 176
TABLE 150 IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 177
TABLE 151 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 177
TABLE 152 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 178
TABLE 153 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 178
8 IMMUNOHISTOCHEMISTRY MARKET, BY END USER 179
8.1 INTRODUCTION 180
TABLE 154 IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 180
8.2 HOSPITALS & DIAGNOSTIC LABORATORIES 180
8.2.1 RISE IN SPECIALTY DIAGNOSTIC TESTS IN LABORATORIES AND IN-HOUSE DIAGNOSTIC PROCEDURES IN HOSPITALS TO DRIVE MARKET 180
TABLE 155 IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 181
TABLE 156 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION) 181
TABLE 157 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION) 182
TABLE 158 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION) 182
8.3 ACADEMIC & RESEARCH INSTITUTES 183
8.3.1 GROWING APPLICATION OF IHC TESTS FOR DRUG DEVELOPMENT STUDIES TO POSITIVELY IMPACT MARKET GROWTH 183
TABLE 159 IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 183
TABLE 160 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 183
TABLE 161 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 184
TABLE 162 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 184
8.4 OTHER END USERS 185
TABLE 163 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 185
TABLE 164 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 185
TABLE 165 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 186
TABLE 166 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 186
9 IMMUNOHISTOCHEMISTRY MARKET, BY REGION 187
9.1 INTRODUCTION 188
TABLE 167 IMMUNOHISTOCHEMISTRY MARKET, BY REGION, 2021–2028 (USD MILLION) 188
9.2 NORTH AMERICA 188
FIGURE 33 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT 189
TABLE 168 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 190
TABLE 169 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 190
TABLE 170 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 190
TABLE 171 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 191
TABLE 172 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 191
TABLE 173 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 192
TABLE 174 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 192
TABLE 175 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 193
TABLE 176 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 193
TABLE 177 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 194
9.2.1 US 194
9.2.1.1 Availability of reimbursements for FDA-approved immunohistochemistry products to promote market 194
TABLE 178 RECENT DEVELOPMENTS IN US IHC MARKET 195
TABLE 179 US: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 195
TABLE 180 US: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 196
TABLE 181 US: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 196
TABLE 182 US: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 197
TABLE 183 US: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 197
TABLE 184 US: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 197
TABLE 185 US: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 198
TABLE 186 US: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 198
TABLE 187 US: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 199
9.2.2 CANADA 199
9.2.2.1 Rise in cancer cases in Canada to propel market growth 199
TABLE 188 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 200
TABLE 189 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 200
TABLE 190 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 201
TABLE 191 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 201
TABLE 192 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 202
TABLE 193 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 202
TABLE 194 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 202
TABLE 195 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 203
TABLE 196 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 203
9.2.3 NORTH AMERICA: RECESSION IMPACT 203
9.3 EUROPE 204
TABLE 197 RECENT DEVELOPMENTS IN EUROPEAN IHC MARKET 204
TABLE 198 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 205
TABLE 199 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 205
TABLE 200 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 206
TABLE 201 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 206
TABLE 202 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 207
TABLE 203 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 207
TABLE 204 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 207
TABLE 205 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 208
TABLE 206 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 208
TABLE 207 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 209
9.3.1 GERMANY 209
9.3.1.1 Germany to dominate European IHC market due to vast research pool and favorable reimbursement policies 209
TABLE 208 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 209
TABLE 209 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 210
TABLE 210 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 210
TABLE 211 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 211
TABLE 212 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 211
TABLE 213 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 211
TABLE 214 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 212
TABLE 215 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 212
TABLE 216 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 213

9.3.2 FRANCE 213
9.3.2.1 Increasing use of IHC in cancer diagnosis and research to drive market 213
TABLE 217 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 214
TABLE 218 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 214
TABLE 219 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 215
TABLE 220 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 215
TABLE 221 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 216
TABLE 222 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 216
TABLE 223 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 216
TABLE 224 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 217
TABLE 225 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 217
9.3.3 UK 217
9.3.3.1 Increase in number of cancer research studies to support market growth 217
TABLE 226 UK: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 218
TABLE 227 UK: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 218
TABLE 228 UK: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 219
TABLE 229 UK: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 219
TABLE 230 UK: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 220
TABLE 231 UK: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 220
TABLE 232 UK: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 220
TABLE 233 UK: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 221
TABLE 234 UK: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 221
9.3.4 ITALY 221
9.3.4.1 High incidence of cancer and rising geriatric population to support market growth in Italy 221
TABLE 235 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 222
TABLE 236 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 222
TABLE 237 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 223
TABLE 238 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 223
TABLE 239 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 224
TABLE 240 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 224
TABLE 241 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 224
TABLE 242 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 225
TABLE 243 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 225
9.3.5 SPAIN 225
9.3.5.1 Spike in demand for personalized medicine to drive demand for IHC tests to find potential biomarkers 225
TABLE 244 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 226
TABLE 245 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 226
TABLE 246 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 227
TABLE 247 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 227
TABLE 248 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 228
TABLE 249 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 228
TABLE 250 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 228
TABLE 251 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 229
TABLE 252 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 229
9.3.6 REST OF EUROPE 229
TABLE 253 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 230
TABLE 254 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 230
TABLE 255 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 231
TABLE 256 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 231
TABLE 257 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 232
TABLE 258 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 232
TABLE 259 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 232
TABLE 260 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 233
TABLE 261 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 233
9.3.7 EUROPE: RECESSION IMPACT 233
9.4 ASIA PACIFIC 234
FIGURE 34 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT 235
TABLE 262 RECENT DEVELOPMENTS IN ASIA PACIFIC IHC MARKET 236
TABLE 263 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 237
TABLE 264 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 237
TABLE 265 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 237
TABLE 266 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 238
TABLE 267 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 238
TABLE 268 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 239
TABLE 269 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 239
TABLE 270 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 239
TABLE 271 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 240
TABLE 272 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 240
9.4.1 CHINA 240
9.4.1.1 Rise in product approvals and shift toward immunoassay diagnostics to fuel market growth 240
TABLE 273 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 241
TABLE 274 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 242
TABLE 275 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 242
TABLE 276 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 243
TABLE 277 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 243
TABLE 278 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 243
TABLE 279 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 244
TABLE 280 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 244
TABLE 281 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 245
9.4.2 JAPAN 245
9.4.2.1 Advancing healthcare expenditure to drive market 245
TABLE 282 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 246
TABLE 283 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 246
TABLE 284 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 247
TABLE 285 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 247
TABLE 286 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 248
TABLE 287 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 248
TABLE 288 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 248
TABLE 289 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 249
TABLE 290 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 249
9.4.3 INDIA 249
9.4.3.1 High-end pathology and diagnostic services to propel market in India 249
TABLE 291 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 250
TABLE 292 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 250
TABLE 293 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 251
TABLE 294 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 251
TABLE 295 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 252
TABLE 296 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 252
TABLE 297 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 252
TABLE 298 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 253
TABLE 299 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 253
9.4.4 AUSTRALIA 253
9.4.4.1 Investment initiatives to drive market growth 253
TABLE 300 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 254
TABLE 301 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 254
TABLE 302 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 255
TABLE 303 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 255
TABLE 304 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 256
TABLE 305 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 256
TABLE 306 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 256
TABLE 307 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 257
TABLE 308 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 257
9.4.5 SOUTH KOREA 257
9.4.5.1 Personalized medicine initiatives to fuel market growth 257
TABLE 309 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 258
TABLE 310 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 258
TABLE 311 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 259
TABLE 312 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 259
TABLE 313 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 260
TABLE 314 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 260
TABLE 315 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 260
TABLE 316 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 261
TABLE 317 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 261
9.4.6 REST OF ASIA PACIFIC 262
TABLE 318 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 262
TABLE 319 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 263
TABLE 320 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 263
TABLE 321 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 264
TABLE 322 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 264
TABLE 323 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 264
TABLE 324 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 265
TABLE 325 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 265
TABLE 326 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 266
9.4.7 ASIA PACIFIC: RECESSION IMPACT 266
9.5 LATIN AMERICA 266
9.5.1 SPIKE IN INCIDENCE OF CANCER IN LATIN AMERICA TO BOOST MARKET 266
TABLE 327 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 267
TABLE 328 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 267
TABLE 329 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 268
TABLE 330 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 268
TABLE 331 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 269
TABLE 332 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 269
TABLE 333 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 269
TABLE 334 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 270
TABLE 335 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 270
9.5.2 LATIN AMERICA: RECESSION IMPACT 270
9.6 MIDDLE EAST & AFRICA 271
9.6.1 GOVERNMENT INITIATIVES FOCUSED ON BOOSTING HEALTHCARE INFRASTRUCTURE DEVELOPMENT TO DRIVE MARKET 271
TABLE 336 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 271
TABLE 337 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 272
TABLE 338 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 272
TABLE 339 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 273
TABLE 340 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 273
TABLE 341 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 273
TABLE 342 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 274
TABLE 343 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 274
TABLE 344 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 275
9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 275
10 COMPETITIVE LANDSCAPE 276
10.1 OVERVIEW 276
10.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 276
FIGURE 35 IMMUNOHISTOCHEMISTRY MARKET: STRATEGIES ADOPTED BY KEY PLAYERS, 2020–2023 277
10.3 MARKET SHARE ANALYSIS 278
FIGURE 36 IMMUNOHISTOCHEMISTRY MARKET: SHARE ANALYSIS OF KEY PLAYERS (2022) 278
10.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 279
FIGURE 37 IMMUNOHISTOCHEMISTRY MARKET: REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS FOR PAST FIVE YEARS 279
10.5 COMPANY EVALUATION QUADRANT 280
10.5.1 STARS 280
10.5.2 EMERGING LEADERS 280
10.5.3 PERVASIVE PLAYERS 280
10.5.4 PARTICIPANTS 280
FIGURE 38 IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION QUADRANT, 2022 281
10.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES 282
10.6.1 PROGRESSIVE COMPANIES 282
10.6.2 STARTING BLOCKS 282
10.6.3 RESPONSIVE COMPANIES 282
10.6.4 DYNAMIC COMPANIES 282
FIGURE 39 IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022 283
10.7 COMPANY PRODUCT FOOTPRINT 284
TABLE 345 IMMUNOHISTOCHEMISTRY MARKET: PRODUCT PORTFOLIO ANALYSIS (2022) 284
10.8 COMPANY REGIONAL FOOTPRINT 285
TABLE 346 IMMUNOHISTOCHEMISTRY MARKET: REGIONAL REVENUE MIX (2022) 285
10.9 COMPETITIVE BENCHMARKING OF START-UPS/SMES 286
TABLE 347 IMMUNOHISTOCHEMISTRY MARKET: DETAILED LIST OF KEY START-UPS/SMES 286
10.10 COMPETITIVE SCENARIO 287
TABLE 348 IMMUNOHISTOCHEMISTRY MARKET: PRODUCT LAUNCHES, JANUARY 2020–MAY 2023 287
TABLE 349 IMMUNOHISTOCHEMISTRY MARKET: DEALS, JANUARY 2020–MAY 2023 288
TABLE 350 IMMUNOHISTOCHEMISTRY MARKET: OTHER DEVELOPMENTS, JANUARY 2020–MAY 2023 289
11 COMPANY PROFILES 290
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
11.1 KEY PLAYERS 290
11.1.1 F. HOFFMANN-LA ROCHE AG 290
TABLE 351 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW 290
FIGURE 40 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2022) 291
11.1.2 DANAHER CORPORATION 299
TABLE 352 DANAHER CORPORATION: BUSINESS OVERVIEW 299
FIGURE 41 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 300
11.1.3 AGILENT TECHNOLOGIES, INC. 306
TABLE 353 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 306
FIGURE 42 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022) 307
11.1.4 THERMO FISHER SCIENTIFIC, INC. 314
TABLE 354 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 314
FIGURE 43 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022) 315
11.1.5 MERCK KGAA 320
TABLE 355 MERCK KGAA: BUSINESS OVERVIEW 320
FIGURE 44 MERCK KGAA: COMPANY SNAPSHOT (2022) 321
11.1.6 BIO-RAD LABORATORIES, INC. 330
TABLE 356 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 330
FIGURE 45 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 331
11.1.7 BIO-TECHNE CORPORATION 336
TABLE 357 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW 336
FIGURE 46 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2022) 337
11.1.8 ABCAM PLC 340
TABLE 358 ABCAM PLC: BUSINESS OVERVIEW 340
FIGURE 47 ABCAM PLC: COMPANY SNAPSHOT (2022) 341
11.1.9 BECTON, DICKINSON AND COMPANY 346
TABLE 359 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 346
FIGURE 48 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) 347
11.1.10 PERKINELMER, INC. 353
TABLE 360 PERKINELMER, INC.: BUSINESS OVERVIEW 353
FIGURE 49 PERKINELMER, INC.: COMPANY SNAPSHOT (2022) 354
11.1.11 TAKARA BIO, INC. 357
TABLE 361 TAKARA BIO, INC.: BUSINESS OVERVIEW 357
FIGURE 50 TAKARA BIO, INC.: COMPANY SNAPSHOT (2022) 358
11.1.12 PHC HOLDINGS CORPORATION 361
TABLE 362 PHC HOLDINGS CORPORATION: BUSINESS OVERVIEW 361
FIGURE 51 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022) 362
11.1.13 CELL SIGNALING TECHNOLOGY, INC. 368
TABLE 363 CELL SIGNALING TECHNOLOGY, INC.: BUSINESS OVERVIEW 368
11.1.14 BIO SB, INC. 372
TABLE 364 BIO SB, INC.: BUSINESS OVERVIEW 372
11.1.15 MILTENYI BIOTEC 377
TABLE 365 MILTENYI BIOTEC: BUSINESS OVERVIEW 377
11.1.16 SAKURA FINETEK JAPAN CO., LTD. 381
TABLE 366 SAKURA FINETEK JAPAN CO., LTD.: BUSINESS OVERVIEW 381
11.1.17 ENZO BIOCHEM, INC. 387
TABLE 367 ENZO BIOCHEM, INC.: BUSINESS OVERVIEW 387
FIGURE 52 ENZO BIOCHEM, INC.: COMPANY SNAPSHOT (2022) 388
11.1.18 ORIGENE TECHNOLOGIES, INC. 393
TABLE 368 ORIGENE TECHNOLOGIES, INC.: BUSINESS OVERVIEW 393
11.2 OTHER PLAYERS 396
11.2.1 EAGLE BIOSCIENCES, INC. 396
TABLE 369 EAGLE BIOSCIENCES, INC.: BUSINESS OVERVIEW 396
11.2.2 BIOCARE MEDICAL, LLC 397
TABLE 370 BIOCARE MEDICAL, LLC: BUSINESS OVERVIEW 397
11.2.3 ELABSCIENCE BIOTECHNOLOGY, INC. 398
TABLE 371 ELABSCIENCE BIOTECHNOLOGY, INC.: COMPANY OVERVIEW 398
11.2.4 BIOGENEX LABORATORIES 400
TABLE 372 BIOGENEX LABORATORIES: COMPANY OVERVIEW 400
11.2.5 DIAGNOSTIC BIOSYSTEMS, INC. 401
TABLE 373 DIAGNOSTIC BIOSYSTEMS, INC.: BUSINESS OVERVIEW 401
11.2.6 HISTO-LINE LABORATORIES 402
TABLE 374 HISTO-LINE LABORATORIES: BUSINESS OVERVIEW 402
11.2.7 ROCKLAND IMMUNOCHEMICALS, INC. 403
TABLE 375 ROCKLAND IMMUNOCHEMICALS, INC.: BUSINESS OVERVIEW 403
11.2.8 GENEMED BIOTECHNOLOGIES, INC. 404
TABLE 376 GENEMED BIOTECHNOLOGIES, INC.: BUSINESS OVERVIEW 404
11.2.9 CANDOR BIOSCIENCE GMBH 406
TABLE 377 CANDOR BIOSCIENCE GMBH: BUSINESS OVERVIEW 406
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
12 APPENDIX 407
12.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 411
12.2 CUSTOMIZATION OPTIONS 413
12.3 RELATED REPORTS 413
12.4 AUTHOR DETAILS 414

★調査レポート[免疫組織化学(IHC)の世界市場予測(~2028):製品別、用途別、エンドユーザー別] (コード:BT4780-23)販売に関する免責事項を必ずご確認ください。
★調査レポート[免疫組織化学(IHC)の世界市場予測(~2028):製品別、用途別、エンドユーザー別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆